Novavax (NVAX) Says FDA Requested Additional Clinical Data

On April 23, 2025, Novavax (NASDAQ: NVAX) issued the following statement:

We believe that our Biologics License Application (“BLA”) is approvable based on conversations with U.S. Food and Drug Administration (“FDA”), as of our Prescription Drug User Fee Act date on April 1 and through today.

We have recently received formal communication from the FDA in the form of an information request for a post marketing commitment (“PMC”) to generate additional clinical data. We look forward to engaging with the FDA expeditiously to address the PMC request and move to approval as soon as possible.

You May Also Be Interested In

• First Advantage to join S&P SmallCap 600, replacing Kennedy-Wilson
• SpaceX prices historic IPO at $135/share in largest ever new listing
• CME Group to launch 24/7 trading for new crude oil and gold contracts